Pre-Screening Funnel Metrics: From Clinical Trial Participant to Enrollment

Roughly 80 percent of clinical trials fail to meet initial enrollment timelines. Research from the Tufts Center for the Study of Drug Development has documented that under-enrollment, rising screen failures, and protracted timelines compound into per-day delay costs that industry analyses have estimated as high as eight million dollars for the most commercially significant programs. By the time these patterns become visible in monthly recruitment reports, the contributing decisions are months old.

Pre-screening funnel metrics surface those patterns earlier. The pre-screening funnel is the path from a candidate's first contact with a study to the moment they are randomized, and each stage produces a measurable signal. Tracked in real time, these signals predict whether enrollment will hit its targets, which sites and sources will outperform, and where the recruitment budget is being consumed without producing enrolled participants.

This article covers six pre-screening funnel metrics that predict enrollment success, what each signals, the benchmarks that contextualize them, and how to turn the data into operational decisions before the study falls behind.

Why the Pre-Screening Funnel Predicts Enrollment Success

Enrollment is the product of a long sequence of conversions. A candidate has to be reached, complete an initial eligibility check, complete a structured pre-screening questionnaire, agree to a site referral, attend an in-person screening visit, and consent to enrollment. Each step has a conversion rate, and the combined effect is multiplicative.

Industry benchmark data illustrates how quickly the math compresses. Clinical research literature suggests a typical conversion ratio of roughly ten candidates identified for every one participant enrolled. Screen failure rates published by the Tufts Center for the Study of Drug Development across Phase II and III trials averaged 36.3 percent in 2016 to 2019, up from 34.7 percent in 2012. In CNS and neuroscience indications, the average has reached 57 percent. Alzheimer's Phase 2 anti-amyloid trials have reported rates above 74 percent.

The cost consequences are documented. Industry estimates place the average cost of a single screen failure at roughly 1,200 dollars, and screen failure rates above 40 percent can cost a typical study in excess of 1.2 million dollars once wasted site activation, coordinator time, and timeline slips are accounted for. Funnel monitoring tells sponsors what is about to go wrong, while there is still time to intervene. The downstream cost picture is covered in The Hidden Cost of Slow Recruitment in Clinical Trials: Why Time-to-First-Patient Matters.

Mapping the Pre-Screening Funnel

A workable operational model groups the candidate journey into four sequential stages, each with a defined entry condition, a measurable exit, and a set of statuses explaining why candidates advance or drop out.

• Primary Screening: initial outreach by a registered nurse through call, SMS, email, WhatsApp, or web chat. A high-level eligibility check based on intake information and nurse judgment, without a structured questionnaire. Exit: Primary Qualified.
• Secondary Screening: a structured pre-screening questionnaire that confirms detailed eligibility against the protocol. Each response feeds a qualification score. Exit: Secondary Qualified.
• Site Screening: the candidate is referred to the nearest viable site, an in-person appointment is booked, and the site team conducts full eligibility verification (labs, imaging, detailed criteria). Exit: Site Visited.
• Recruited: final enrollment. The participant has met all eligibility criteria and consented. Subsequent trial activity (randomization, study visits, outcome tracking) is managed in the study's clinical systems.

Each stage is a measurable conversion point with a typical drop-off rate, a typical cost per conversion, and a defined set of statuses that record why candidates exit. Primary Screening exit statuses include Did Not Pick, Wrong Phone Number, Not Reachable, Junk Lead, Follow Up, and Inbound Call/Message. Secondary Screening exit statuses include SS Failed, Not Interested, Abandoned, and Reverted. Site Screening outcomes resolve to either Recruited or Site Scr Failed. This taxonomy is what makes funnel data analytically useful: drop-offs are categorized at the point they occur.

The site-level mechanics of effective pre-screening are explored in Pre-Screening Smarter: How Technology Reduces Screen Failures at Sites.

The Funnel Metrics That Predict Enrollment Success

Six metrics carry the most predictive weight in the published literature and current industry practice. Each signals something specific about whether enrollment is on track, where investment is paying off, and which interventions will move the funnel if applied early.

Source-Attributed Conversion Rate

The percentage of candidates from a given recruitment channel who eventually enroll, tracked from intake through to Recruited status. Attribution is typically captured at three levels: medium (the broad channel, for example social media or radio), campaign (for example Diabetes Screening Drive), and source (for example Instagram or Facebook). Channel performance varies considerably: physician referrals convert above 20 percent and participant-to-participant referrals at roughly 23 percent at low cost, while digital channels show lower conversion but substantially higher reach. Industry benchmarks suggest digital campaigns can reduce cost per enrolled participant by 25 to 40 percent when paired with site-based outreach. Sponsors who reallocate budgets based on source-attributed conversion rather than top-of-funnel inquiry volume see faster enrollment and lower cost.

Primary Screening Conversion Rate

The percentage of New Participants who reach Primary Qualified status. Low conversion is a signal about contactability and intake quality before it is a signal about eligibility. Drop-offs typically resolve to a contact-failure status (Did Not Pick, Wrong Phone, Not Reachable, Junk Lead) rather than to a confirmed disqualification. A Tufts CSDD survey of more than 2,000 physicians and nurses found that physicians refer less than 0.2 percent of their patients into clinical trials. The share of inquiry-stage candidates who reach structured pre-screening is similarly lossy without intentional outreach cadence and contact strategy. Low Primary conversion predicts a continued shortfall further down the funnel regardless of top-of-funnel volume.

Secondary Screening Pass Rate

The percentage of Primary Qualified candidates who, after completing the structured pre-screening questionnaire, reach Secondary Qualified status. A low pass rate is often interpreted as a candidate-quality problem, but more frequently signals a protocol-design problem. Inclusion and exclusion criteria that exclude a large share of the target population produce low pass rates and high downstream cost per enrolled participant. The cumulative effect of restrictive criteria is one structural driver of the rising screen-failure rates Tufts CSDD has observed over the past decade, particularly in CNS and rare-disease indications. Sponsors who monitor pass rate against known prevalence catch protocol over-restriction early enough to consider amendment options before the timeline is at risk.

Referral-to-Appointment Conversion Rate

The percentage of Secondary Qualified candidates who are referred to a site and complete the in-person screening appointment. Drop-off between Secondary Qualified and Site Visited is driven by logistical or psychological friction: site location, visit burden, travel costs, candidate confidence. Closer sites improve attendance. A conversion below the planning assumption predicts site-level under-enrollment even when Secondary Screening pass rates look healthy. Tufts CSDD has documented that approximately 11 percent of activated investigative sites fail to enroll a single patient (13 percent in North America), and roughly 40 percent of activated sites under-enroll. The pattern shows up early in the referral-to-appointment data.

Site Screening Pass Rate

The percentage of referred candidates who pass site-level screening and reach Recruited rather than Site Scr Failed. High Site Scr Failed rates signal where pre-screening quality is lowest: a site or source generating high Site Scr Failed volumes is producing referrals the earlier stages should have caught. Industry analyses of cancer trials report per-patient screening costs of approximately 2,000 dollars, and screen failure rates range from 20 to 30 percent in genitourinary cancers to 70 to 80 percent in Alzheimer's trials. Peer-reviewed studies of AI clinical decision support systems for cancer trial eligibility have demonstrated greater than 80 percent accuracy, and a 2026 Nature Communications study reported that AI augmentation can approximate or improve staff prescreening accuracy without efficiency loss. Sponsors who tie Site Scr Failed rates back to source and pre-screening method address the upstream weak points rather than absorbing the cost downstream. The site-level operational levers are covered in Reducing Screen Failures in Clinical Trials: How Sites Can Improve Eligibility Matching.

Cost per Recruited Participant

Total recruitment spend divided by the count of Recruited participants. It is the ultimate measure of recruitment efficiency, compounding every inefficiency upstream: wasted spend on low-converting sources, friction-driven drop-offs, Site Scr Failed overhead, site-level variation. Recent industry analyses place average per-patient costs in Phase III trials at roughly 113,000 dollars, with oncology commanding a substantial premium because of biomarker testing, advanced imaging, and extended survival follow-up. Monitoring this metric in real time, not at end of study, lets sponsors intervene before the recruitment budget is exhausted.

Turning Funnel Metrics Into Sponsor Action

Knowing the metrics is not the same as acting on them. Sponsors who get operational value from pre-screening funnel data share three practices: real-time dashboards rather than monthly reports, defined intervention thresholds rather than ad-hoc judgment calls, and structured workflows that capture funnel data consistently across sites and sources.

Real-time visibility is the foundation. A sponsor reviewing recruitment data once a month is operating on a four-week lag. A weekly or daily cadence, supported by dashboards that surface KPIs at every stage, lets sponsors see the signal while there is still time to redirect.

Defined intervention thresholds remove judgment lag. A sponsor that has agreed in advance on what triggers a source-shift decision, a site-level conversation, or a protocol-amendment review is not negotiating each decision in the moment. The FDA's Diversity Action Plan requirements under FDORA require sponsors to demonstrate upfront how they will achieve representation goals, raising the operational stakes for source and site attribution analytics from day one of recruitment.

Workflow consistency is what makes the data trustworthy. If candidate source is captured inconsistently, source-attributed conversion is unreliable. If pre-screening uses different criteria at different sites, pass rates cannot be compared. Platforms that produce reliable funnel data standardize the workflow before the candidate enters it.

DecenTrialz is a participant screening platform for sponsors, CROs, and research sites in the United States. The platform runs the four-stage pipeline above and surfaces it through a Trial Dashboard with six KPI cards (Total Participants, New Participants, Primary Qualified, Secondary Qualified, Site Referrals, Recruited Participants) plus a horizontal Participant Pipeline funnel with real-time counts at each stage. A Qualification Summary donut chart visualizes Total versus Primary Qualified versus Secondary Qualified to surface conversion problems. Each participant carries a qualification score from 0 to 100 that updates automatically as screening data is captured. Medium, campaign, and source attribution fields follow each candidate from intake to enrollment, making source-attributed conversion measurable rather than estimated. Operational scope sits at the pre-screening stage: a registered nurse completes Primary and Secondary Screening before the candidate is referred to the site. Final eligibility verification, informed consent, and enrollment are always handled by the study team. Sponsors can review the platform at decentrialz.com. The role of dashboards in sponsor oversight is explored in Data-Driven Decisions: How Dashboards Transform Sponsor Oversight.

Next Steps for Sponsors

Pre-screening funnel monitoring is an operational discipline. Sponsors who get value from funnel metrics start with four decisions:

• Define the funnel stages, with explicit conversion definitions and exit statuses so drop-offs are categorized at the point they occur.
• Decide which of the six metrics will be tracked and the planning assumption for each, calibrated to current industry benchmarks.
• Select a dashboard cadence (daily, twice weekly, or weekly) and assign owners on the sponsor side.
• Set intervention thresholds in advance for source shifts, site conversations, and protocol-amendment reviews.

A sponsor who completes these four decisions before activating the first site has a forecasting capability that retrospective analysis cannot produce. The benchmarks cited above are reference inputs, not destinations. Each sponsor's funnel will run on different math depending on therapeutic area, geography, and protocol design. The metrics are available from week one. The decision is whether to use them. Sponsors evaluating platforms that surface pre-screening funnel data in real time can start at decentrialz.com. The broader platform-evaluation criteria are covered in Partnering for Success: What Sponsors Should Look for in a Recruitment Platform.